



Stockholm, 2019-07-16

PRESS RELEASE

An additional patent is granted for the EU

QuiaPEG Pharmaceuticals Holding AB (publ) has been granted another patent in the EU.

The granted European patent broadens and strengthens QuiaPEG's growing patent portfolio and the protection of the phosphotriester linker that can be used both for permanent and releasable pegylation of various drugs. The patent will be published in the European Patent Bulletin on August 7, 2019 with patent number 2858678.

With the granting of this patent, the QuiaPEG patent portfolio now consists of two approved patents in the EU, eight approved patents in the US and a granted patent in Australia.

For further information, please contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53 e-mail: marcus.bosson@quiapeg.com www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the above contact person, for publication on December 11th, 2018.

About QuiaPEG Pharmaceuticals Holding AB (publ)

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, such as biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. QuiaPEG is listed on the Spotlight Stock Market in Stockholm.